Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXELDERM vs AMPHOTERICIN B
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.
Tinea pedis,Tinea cruris,Tinea corporis,Tinea versicolor
Aspergillosis,Blastomycosis,Candidiasis,Coccidioidomycosis,Cryptococcosis,Histoplasmosis,Mucormycosis,Sporotrichosis,Visceral leishmaniasis,Empiric therapy for febrile neutropenia,Meningitis (cryptococcal, coccidioidal)
Apply a thin layer to affected skin twice daily (morning and evening).
0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Terminal half-life: 24–48 hours initially, prolonged to 15 days with repeated dosing due to tissue redistribution.
Minimal systemic absorption; when absorbed, primarily metabolized in the liver via oxidation and glucuronidation.
Primarily hepatic; exact enzymes not well characterized.
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
Renal: ~2-5% unchanged; biliary/fecal: ~40% as metabolites; extensive tissue binding delays excretion.
Not applicable; systemic levels are undetectable with topical use.
90–95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Not applicable; negligible systemic absorption.
4–5 L/kg (extensive tissue binding, especially in liver, spleen, and lungs).
Topical: negligible systemic bioavailability (<1%) due to poor percutaneous absorption.
IV: 100%; oral: <5%; topical: minimal systemic absorption.
No dosage adjustment required for renal impairment.
Acute kidney injury: consider dose reduction or switch to liposomal formulation. No specific GFR-based dose adjustments for conventional formulation; monitor renal function and electrolytes. For liposomal amphotericin B, no dosage adjustment required for renal impairment. Continuous renal replacement therapy: conventional amphotericin not recommended due to nephrotoxicity; liposomal preferred.
No dosage adjustment required for hepatic impairment.
No specific Child-Pugh based dose adjustments. Use caution in hepatic impairment; monitor liver function tests. Dose adjustment not typically required.
Safety and efficacy in pediatric patients below 12 years have not been established; see prescribing information for age-specific recommendations.
Conventional amphotericin B: 0.25-1.5 mg/kg/day IV; initial test dose 0.1 mg/kg. Liposomal amphotericin B: 3-5 mg/kg/day IV. For neonates: 1 mg/kg/day. Maximum daily dose: 1.5 mg/kg for conventional, 5 mg/kg for liposomal.
No specific geriatric dose adjustments; use caution due to higher risk of adverse effects from prolonged use.
Use with caution due to age-related renal function decline; monitor renal function and electrolyte levels carefully. Same dosing as adults; adjust for renal impairment if present. Lower doses may be considered based on clinical status.
None.
Amphotericin B should be used primarily for progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of fungal disease. It should be used under close medical supervision due to potential toxicity.
Avoid contact with eyes, nose, mouth, or other mucous membranes. Discontinue if irritation or sensitization occurs. Not for oral or ophthalmic use. Use in children under 12 years not established.
Monitor renal function, electrolytes, and liver function; risk of nephrotoxicity, hypokalemia, hypomagnesemia, and infusion-related reactions; caution in patients with renal impairment and those receiving other nephrotoxic drugs.
Known hypersensitivity to sulconazole or any component of the formulation.
Hypersensitivity to amphotericin B or any component of the formulation; unless the potential benefit outweighs the risk.
None known.
Avoid excessive salt intake; monitor for hypokalemia and hypomagnesemia. No specific food restrictions but maintain adequate hydration.
Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.
FDA Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies in first trimester. Use during pregnancy only if clearly needed. Limited data suggest no increased risk of major malformations across all trimesters.
Not known if excreted in breast milk. Caution in nursing mothers; limited data. M/P ratio not available.
Excreted in breast milk in low levels; M/P ratio not established. Consideration of benefits vs risks; caution in nursing infants due to potential for oral absorption and adverse effects.
No dose adjustment required for topical use; insufficient data for systemic absorption changes.
No specific dose adjustments recommended in pregnancy; standard dosing based on indication and patient weight. Pharmacokinetic changes in pregnancy (increased Vd, increased clearance) may theoretically require higher doses, but clinical data insufficient to recommend adjustment.
Apply sparingly to affected area; avoid use on mucous membranes or intertriginous areas. Discontinue if irritation occurs. Not recommended for use under occlusive dressings.
Premedicate with acetaminophen, diphenhydramine, and hydrocortisone to reduce infusion-related reactions. Monitor serum potassium and magnesium closely due to renal wasting. Use normal saline bolus before infusion to reduce nephrotoxicity. Lipid formulations allow higher doses with less nephrotoxicity. Amphotericin B deoxycholate is reserved for severe, refractory cases.
Use only on the skin as directed; avoid contact with eyes, mouth, or open wounds.,Wash hands before and after applying unless treating hands.,Do not cover the treated area with bandages or wrappings unless directed by a doctor.,Stop use and consult doctor if condition worsens or does not improve within 2 weeks.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
You may experience fever, chills, and nausea during infusion; these are common and can be managed with premedications.,Report any signs of kidney problems such as decreased urine output, swelling in legs, or fatigue.,Avoid potassium and magnesium supplements unless prescribed, as levels may fluctuate.,This medication can cause low blood pressure during infusion; rise slowly from sitting or lying down.,Complete the full course even if you feel better to prevent the infection from returning.
No interactions on record
"Efinaconazole, a triazole antifungal, inhibits fungal CYP450-dependent lanosterol 14α-demethylase, reducing ergosterol synthesis. Amphotericin B binds to ergosterol in fungal membranes, forming pores that cause cell death. Concomitant use may decrease Amphotericin B efficacy because efinaconazole depletes ergosterol, the target for Amphotericin B, potentially attenuating the polyene's antifungal activity, especially in systemic fungal infections."
"Gentamicin, an aminoglycoside antibiotic, and Amphotericin B, a polyene antifungal agent, both independently induce nephrotoxicity. Concurrent administration synergistically increases the risk of acute kidney injury, characterized by elevated serum creatinine, reduced glomerular filtration rate, and potential tubular necrosis. This additive nephrotoxic effect necessitates cautious use and enhanced monitoring."
"Amphotericin B, a polyene antifungal, can cause hypokalemia and hypomagnesemia due to renal tubular damage. Isradipine, a calcium channel blocker, may also affect electrolyte balance. Concomitant use increases the risk of severe hypokalemia, potentially leading to cardiac arrhythmias, QT prolongation, and neuromuscular effects. Close monitoring of serum electrolytes and ECG is essential."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXELDERM vs AMPHOTERICIN B, answered by our medical review team.
EXELDERM is a Topical Antifungal that works by Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.. AMPHOTERICIN B is a Antifungal that works by Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXELDERM and AMPHOTERICIN B depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXELDERM is: Apply a thin layer to affected skin twice daily (morning and evening).. The standard adult dose of AMPHOTERICIN B is: 0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXELDERM and AMPHOTERICIN B in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXELDERM is classified as Category C. Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.. AMPHOTERICIN B is classified as Category C. FDA Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies in first trimester. Use during pregnancy only if clearly needed. Limited data sug. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.